^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ATOR-1015
i
Other names: ATOR-1015, ADC-1015
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Alligator Biosci, BioInvent
Drug class:
CTLA4 inhibitor, OX40 agonist
Related drugs:
16d
First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies. (PubMed, ESMO Open)
Although considered safe, the treatment induced neutralizing anti-drug antibodies in most patients, leading to IRRs and reduced efficacy due to low serum exposure, an effect that could not be overcome by increasing doses. Future development requires re-engineering the therapeutic format to minimize immunogenicity, thereby improving both safety and effectiveness.
Clinical • P1 data • Journal • First-in-human
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • ICOS (Inducible T Cell Costimulator)
|
Yervoy (ipilimumab) • ATOR-1015
over5years
[VIRTUAL] Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies (SITC 2020)
Following the dose escalation phase, an expansion cohort for patients with advanced malignant melanoma will be initiated. Ethics Approval The study is approved by the Ethic Boards in Sweden and Denmark.
Clinical • P1 data • PK/PD data • IO biomarker
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
ATOR-1015
over5years
[VIRTUAL] Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies (SITC 2020)
Following the dose escalation phase, an expansion cohort for patients with advanced malignant melanoma will be initiated. Ethics Approval The study is approved by the Ethic Boards in Sweden and Denmark.
Clinical • P1 data • PK/PD data • IO biomarker
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
ATOR-1015
6years
[VIRTUAL] A first-in-human phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody. (ASCO 2020)
The dosing of ATOR-1015 has been safe and well-tolerated up to 200 mg. Dose escalation continues and the current dose level under evaluation is 400 mg. Research Funding: Alligator Bioscience AB
Clinical • P1 data
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TNFRSF4 (TNF Receptor Superfamily Member 4)
|
ATOR-1015
6years
[VIRTUAL] A first-in-human phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody (AACR-I 2020)
The dosing of ATOR-1015 has been safe and well-tolerated up to 100 mg. Dose escalation continues and the current dose level is 200 mg.
Clinical • P1 data
|
TNFRSF4 (TNF Receptor Superfamily Member 4)
|
ATOR-1015
Share via
